ObsEva SA (OBSV)
| Market Cap | 197.60M |
| Revenue (ttm) | 19,000 |
| Net Income (ttm) | -82.08M |
| Shares Out | 77.95M |
| EPS (ttm) | -1.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 816,321 |
| Open | 2.58 |
| Previous Close | 2.61 |
| Day's Range | 2.53 - 2.66 |
| 52-Week Range | 1.86 - 5.55 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 12.00 (+352.8%) |
| Est. Earnings Date | Nov 4, 2021 |
About OBSV
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for pret...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ObsEva stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 352.83% from the latest price.
News
ObsEva Presents Linzagolix Data From Uterine Fibroid Trials
ObsEva SA (NASDAQ: OBSV) has announced data from PRIMROSE (1 and 2) Phase 3 study of linzagolix for uterine fibroids. The data were presented at the American Society for Reproductive Medicine (ASRM) 202...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 S...
- Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster -
ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & ...
– Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagoli x for the treatment of severe adenomyosis –
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
ObsEva Announce s Relationship with Syneos Health to Commercialize Linzagolix
ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids
ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
- If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids -
ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
GENEVA, Switzerland September 7 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today an...
5 Penny Stocks To Watch For September With Upcoming Events
These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Inform...
7 Hottest Penny Stocks to Pick Up Now
Penny stocks from companies that have reasonable business fundamentals. Stocks that can possibly provide multi-fold returns.
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
- Linzagolix (Yselty ® ) for uterine fibroids: US New Drug Application filing planned in Q 3 :21 ; European marketing approval recommendation anticipated in Q4:21 -
ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Liv...
- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patient s Across Three Randomized , Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction-
ObsEva to Present at Upcoming Investor Conferences
GENEVA, Switzerland August 3 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today annou...
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigationa...
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i ; agent is being studied in an area of significant unmet need
Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock?
Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia –
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyos...
-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer -
ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting
ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
- D ata from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous p reterm labor to be discussed in an oral presentation -
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28,...
Geneva, Switzerland and Boston, MA – May 31 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive ...
ObsEva Announces Proposed Changes to the Composition of its Board of Directors
Geneva, Switzerland and Boston, MA – May 25 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive h...
OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today
Swiss biopharma ObsEva is on course to introduce an oral treatment for uterine fibroids, which affect 80% of women by menopause. The post OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today ap...